Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of Residual Motion Within the Gating Window on Dose Distribution in Respiratory-gated Proton Therapy.

In vivo (Athens, Greece)·2026
Same author

Special Issue "Breast Cancer: From Pathophysiology to Novel Therapies".

International journal of molecular sciences·2026
Same author

Contour and dosimetric evaluation of an in-room mobile CBCT scanner for cylinder based brachytherapy.

Brachytherapy·2026
Same author

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

Science advances·2026
Same author

American Brachytherapy Society consensus guidelines for medical physics residency training endorsed by the American Association of Physicists in Medicine, Part I: High-dose-rate remote afterloader brachytherapy.

Brachytherapy·2026
Same author

Assessment of soft error risks to cardiac implantable electronic devices for boron neutron capture therapy using field-programmable gate arrays.

Japanese journal of radiology·2026

Related Experiment Video

Updated: Jul 16, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Actinium-225 Targeted Agents: Where Are We Now?

Firas Mourtada1, Katsumi Tomiyoshi2, Jennifer Sims-Mourtada3

  • 1Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA.

Brachytherapy
|September 10, 2023
PubMed
Summary

Actinium-225 (²²⁵Ac) alpha-particle therapy offers precise cancer treatment with fewer side effects. Advances in ²²⁵Ac production and dosimetry are crucial for its effective clinical use in brachytherapy.

Keywords:
(225)AcChelationDosimetryImagingTheranostics

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

498

Related Experiment Videos

Last Updated: Jul 16, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

498

Area of Science:

  • Nuclear Medicine
  • Radiation Oncology
  • Medical Physics

Background:

  • Alpha-particle targeted radionuclide therapy presents a promising approach for cancer management.
  • High linear energy transfer (LET) alpha emitters offer advantages over beta and gamma emitters, including targeted tumor cell kill and reduced normal tissue damage.

Purpose of the Study:

  • To review recent advancements in Actinium-225 (²²⁵Ac) targeted radionuclide therapy.
  • To address challenges in ²²⁵Ac source production, dosimetry, and clinical application for brachytherapy.

Main Methods:

  • Literature review of recent studies on ²²⁵Ac production and characterization.
  • Analysis of dosimetry modeling techniques for ²²⁵Ac brachytherapy.
  • Summary of current clinical trials and outcomes using ²²⁵Ac.

Main Results:

  • Actinium-225 (²²⁵Ac) shows significant potential due to its physical and chemical properties for brachytherapy.
  • Challenges remain in ²²⁵Ac source availability, standardized dosimetry, and radiopharmaceutical production.
  • Empirical dosing of ²²⁵Ac may lead to variable outcomes and toxicity.

Conclusions:

  • Continued research in ²²⁵Ac production and dosimetry is essential for optimizing targeted radionuclide therapy.
  • Standardized protocols are needed for safe and effective clinical implementation of ²²⁵Ac brachytherapy.
  • Future directions include improved modeling and clinical studies to refine treatment strategies.